• No significant differences when tapering TNF blockers vs csDMARDs

    Tapering csDMARDs or anti-TNF showed no significant differences in flare ratios, disease activity, functional ability and quality of life between both tapering strategies in the first 12 months of follow-up.

  • Early breast cancer: adjuvant chemotherapy often unnecessary

    A study concludes that if a mean recurrence score of 11-25 is found in women with early hormone-receptor-positive HER2-negative breast carcinoma without axillary lymph nodes using a 21 gene expression test, adjuvant chemotherapy may be dispensed with.

  • A Parisian mayor launches a rat monitoring site

    Paris is seeing an exponential population explosion of rats. A local elected official has taken on the internet and the public to tackle the issue.

  • Early, intensive RA treatment normalises mortality rates

    Data from the Dutch COBRA study show a normalization of rheumatoid arthritis (RA) mortality when compared to the general population after 23 years of follow-up. These findings confirm that early, intensive treatment of RA offers long-term benefits and strongly suggest these benefits include normalization of mortality.

  • Nelarabine achieves a 4-year survival of 90% in T-cell Acute Lymphoblastic Leukemia

    Unprecedented 4-year survival rates can be achieved with first-line therapy in children and adolescents with T-cell Acute Lymphoblastic Leukemia (T-ALL) with the additional administration of nelarabine to COG’s augmented Berlin-Frankfurt-Münster (aBFM) chemotherapy regime.

  • Do methotrexate and other treatment agents protect rheumatic patients against dementia?

    Can conventional rheumatism drugs halve the risk of dementia in patients with rheumatoid arthritis? A large cohort study data hints at this and gives a particular protective potential for methotrexate.

  • Could ibrutinib become the new therapy standard for Waldenström's macroglobulinemia (WM)?

    In patients with Waldenström's macroglobulinemia (WM), the additional administration of ibrutinib to rituximab can reduce the risk of progression or death by relatively 80% compared to rituximab-only treatment.

  • Advanced hepatocellular carcinoma: More treatments options ahead

    Transarterial chemoembolization and external radiation therapy have been extensively investigated in combination for improved survival for this stage. However, recent trial shows that HCC patients with vascular invasion might benefit from such a combination as well.

  • Atezolizumab and chemotherapy approach for NSCLC with squamous epithelial histology

    Patients with advanced non-small cell lung cancer (NSCLC) with squamous epithelial histology may benefit from an additional dose of the PD-L1 inhibitor atezolizumab in addition to chemotherapy in first-line treatment compared to chemotherapy alone.

  • Exoskeletons at the workplace: blessing or curse?

    The number of injury-related work absences and the rising reasons behind them is raising concerns. Exoskeletons could be of help to protect a worker's health, but how secure are these complex systems?

  • Vitamins B6 and B12 raise the risk of lung cancer in men

    Vitamin supplements are also widely used in many European countries. However, a US study showed that vitamins B6 and B12, taken as individual nutritional supplements, may have a role in male lung cancer incidence.

  • Google seeks to expand into digital health

    Google is a crucial bidder for Nokia Healthcare, a Nokia subdivision focusing on smart health-related products.

  • Higher tumor mutation burden predicts better response to checkpoint inhibitors

    A recent issue of the New England Medical Journal features a study which tested two new biological agents, nivolumab, and ipilimumab, against chemotherapy in a specific population of non-small-cell lung cancer patients - those with a high tumor mutation burden (TMB).

  • Methotrexate in early rheumatoid arthritis: Are higher doses not superior to low-dose therapies?

    Recent data questions high dose usage in the early therapy phases for rheumatoid arthritis (RA) with oral methotrexate (MTX).

  • Link found between breast implants and anaplastic large cell lymphoma

    Awareness of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) began to rise in 2011 when the FDA released a report on some of these cases. Since then, several studies confirmed this interlink with a recent Dutch population-based, case-control study adding crucial insights into it.

  • Increased risk for heart failure within 6 weeks after giving birth

    A study from the University of Illinois at Chicago has found that women are at the highest risk for heart failure within the six weeks after delivery, known as the postpartum period.

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) such as Ibuprofen may be able to prevent Alzheimer’s

    Scientists have proposed that once individuals at risk of developing Alzheimer’s have been identified, a low-dose ibuprofen prophylaxis can be started to stop Alzheimer’s in its tracks.

  • US medical school launches early phase HIV vaccine clinical trial

    Based on the available scientific knowledge and pre-clinical evidence, the University of Massachusetts Medical School has initiated multicenter, phase I clinical trial to investigate an HIV vaccine that might prevent HIV infection.

  • Parkinson's: Skin test enables early diagnosis

    Scientists succeeded in detecting Parkinson's disease through a minimally invasive skin biopsy - years before the patient becomes noticeably ill.

  • Coronary stenting with stable CHD: no advantages over placebo?

    Percutaneous Coronary Interventions (PCI) play a major role in cardiology, as they are the gold standard for the treatment of narrowed (stenosed) coronary vessels. However, the highly acclaimed stents are the target of new criticism.

  • 80 |
  • 81 |
  • 82 |
  • 83 |
  • 84 |
  • 85 |
  • 86 |
  • 87 |
  • 88 |
  • 89 |
  • 90 |